Coagulation, platelets, and acute pancreatitis

Pancreas

Volumn 34, Issue 1, 2007, Pages 15-20

  Kakafika, Anna ^a   Papadopoulos, Vasilios ^b   Mimidis, Konstantinos ^b   Mikhailidis, Dimitri P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Acute pancreatitis; Coagulation; Inflammatory mediators; Platelet; Tissue factor

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CD31 ANTIGEN; DICLOFENAC; ENDOTHELIN RECEPTOR ANTAGONIST; GINKGOLIDE B; HEPARIN; KETANSERIN; LEXIPAFANT; MONOCLONAL ANTIBODY; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; R 96544; RECOMBINANT ENZYME; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; RESVERATROL; RITANSERIN; SEROTONIN ANTAGONIST; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; CLINICAL STUDY; CLINICAL TRIAL; DRUG TREATMENT FAILURE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; EXPERIMENTAL ANIMAL; EXPERIMENTAL STUDY; HEMATOLOGICAL PARAMETERS; HEMOSTASIS; HUMAN; HYPOTHERMIA; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEPSIS; THROMBOCYTE ACTIVATION;

ACUTE DISEASE; ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; HUMANS; PANCREATITIS;

EID: 33846013600     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpa.0000240617.66215.d2     Document Type: Review

References (85)

1. Bhatia M, Wong FL, Cao Y, et al. Pathophysiology of acute pancreatitis. Pancreatology. 2005;5:132-144.
2. Dominguez-Munoz JE, Viedma JA, Perez-Mateo M, et al. Inflammatory response in the initial phase of acute pancreatitis: relationship to the onset and severity of the disease. Rev Esp Enferm Dig. 1995;87:225-246.
3. McKay CJ, Buter A. Natural history of organ failure in acute pancreatitis. Pancreatology. 2003;3:111-114.
4. Imrie CW. Acute pancreatitis: overview. Eur J Gastroenterol Hepatol. 1997;9:103-105.
5. Bhatia M. Novel therapeutic targets for acute pancreatitis and associated multiple organ dysfunction syndrome. Curr Drug Targets Inflamm Allergy. 2002;1:343-351.
6. Rinderknecht H. Fatal pancreatitis, a consequence of excessive leukocyte stimulation? Int J Pancreatol. 1988;3:105-112.
7. Bhatia M, Saluja AK, Hofbauer B, et al. Neutral endopeptidase (NEP) plays an anti-inflammatory role in acute pancreatitis and pancreatitis-associated lung injury. Pancreas. 1997;15:428.
8. Algul H, Tando Y, Schneider G, et al. Acute experimental pancreatitis and NF-kappaB/Rel activation. Pancreatology. 2002;2:503-509.
9. Granger J, Remick D. Acute pancreatitis: models, markers, and mediators. Shock. 2005;24(suppl 1):45-51.
10. Ranson JH, Lackner H, Berman IR, et al. The relationship of coagulation factors to clinical complications of acute pancreatitis. Surgery. 1977;81:502-511.
11. Agarwal N, Pitchumoni CS. Acute pancreatitis: a multisystem disease. Gastroenterologist. 1993;1:115-128.
12. Bockman DE, Buchler M, Beger HG. Ultrastructure of human acute pancreatitis. Int J Pancreatol. 1986;1:141-153.
13. Jacobs RM, Murtaugh RJ, Fertel RH. Platelet function in experimentally induced pancreatitis in the dog. Thromb Haemost. 1986;55:197-200.
14. Lukaszyk A, Bodzenta-Lukaszyk A, Gabryelewicz A, et al. Does acute experimental pancreatitis affect blood platelet function? Thromb Res. 1989;1:319-325.
15. Feldman BF, Attix EA, Strombeck DR, et al. Biochemical and coagulation changes in a canine model of acute necrotizing pancreatitis. Am J Vet Res. 1981;42:805-809.
16. Kerekes L, Arkossy P, Altorjay I, et al. Evaluation of hemostatic changes and blood antioxidant capacity in acute and chronic pancreatitis. Hepatogastroenterology. 2001;48:1746-1749.
17. Redha F, Uhlschmid G, Ammann RW, et al. Injection of microspheres into pancreatic arteries causes acute hemorrhagic pancreatitis in the rat: a new animal model. Pancreas. 1990;5:188-193.
18. Lasson A, Ohlsson K. Consumptive coagulopathy, fibrinolysis and protease-antiprotease interactions during acute human pancreatitis. Thromb Res. 1986;41:167-183.
19. Aasen AO, Kierulf P, Ruud TE, et al. Studies on pathological plasma proteolysis in patients with acute pancreatitis. A preliminary report. Acta Chir Scand Suppl. 1982;509:83-87.
20. Radenkovic D, Bajec D, Karamarkovic A, et al. Disorders of hemostasis during the surgical management of severe necrotizing pancreatitis. Pancreas. 2004;29:152-156.
21. Salomone T, Tosi P, Palareti G, et al. Coagulative disorders in human acute pancreatitis: role for the D-dimer. Pancreas. 2003;26:111-116.
22. Mimidis K, Papadopoulos V, Kotsianidis J, et al. Alterations of platelet function, number and indexes during acute pancreatitis. Pancreatology. 2004;4:22-27.
23. Lechin F, van der Dijs B. Platelet aggregation, platelet serotonin and pancreatitis. JOP. 2004;5:237-238.
24. Barradas MA, Mikhailidis DP. Serotonin, histamine and platelets in vascular disease with special reference to peripheral vascular disease. Braz J Med Biol Res. 1992;25:1063-1076.
25. Prinz RA, Fareed J, Rock A, et al. Platelet activation by human pancreatic fluid. J Surg Res. 1984;37:314-319.
26. De Clerck F, David JL, Janssen PA. Inhibition of 5-hydroxytryptamine- induced and -amplified human platelet aggregation by ketanserin (R 41468), a selective 5-HT2-receptor antagonist. Agents Actions. 1982;12:388-397.
27. Hara H, Osakabe M, Kitajima A, et al. MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist. Thromb Haemost. 1991;65:415-420.
28. Marcus AJ. Platelet aggregation. In: Coleman RW, Hirsch J, Marder VJ, et al, eds. Hemostasis and Thrombosis Basic Principles and Clinical Practice. Philadelphia, PA: Lippincott; 1982;380-389.
29. Oguchi H, Terashima M, Koiwai T, et al. Effects of the S2-serotonergic receptor antagonist, ketanserin, on cerulein-induced pancreatitis in the rat. Life Sci. 1992;50:733-737.
30. Yoshino T, Yamaguchi I. Possible involvement of 5-HT2 receptor activation in aggravation of diet-induced acute pancreatitis in mice. J Pharmacol Exp Ther. 1996;283:1495-1502.
31. Ogawa T, Sugidachi A, Tanaka N, et al. Effects of R-102444 and its active metabolite R-96544, selective 5-HT2A receptor antagonists, on experimental acute and chronic pancreatitis: additional evidence for possible involvement of 5-HT2A receptors in the development of experimental pancreatitis. Eur J Pharmacol. 2005;521:156-163.
32. Huval WV, Lelcuk S, Shepro D, et al. Role of serotonin in patients with acute respiratory failure. Ann Surg. 1984;200:166-172.
33. Lindstrom O, Kylanpaa L, Mentula P, et al. Upregulated but insufficient generation of activated protein C is associated with development of multiorgan failure in severe acute pancreatitis. Crit Care. 2006;10:R16.
34. Mimidis K, Papadopoulos V, Kartasis Z, et al. Assessment of platelet adhesiveness and aggregation in mild acute pancreatitis using the PFA-100 system. JOP. 2004;5:132-137.
35. Johnson CD. Platelet-activating factor and platelet-activating factor antagonists in acute pancreatitis. Dig Surg. 1999;16:93-101.
36. Formela LJ, Galloway SW, Kingsnorth AN. Inflammatory mediators in acute pancreatitis. Br J Surg. 1995;82:6-13.
37. Kald B, Kald A, Ihse I, et al. Release of platelet-activating factor in acute experimental pancreatitis. Pancreas. 1993;8:440-442.
38. Anderson BO, Bensard DD, Harken AH. The role of platelet activating factor and its antagonists in shock, sepsis and multiple organ failure. Surg Gynecol Obstet. 1991;172:415-424.
39. Bedirli A, Gokahmetoglu S, Sakrak O, et al. Beneficial effects of recombinant platelet-activating factor acetylhydrolase and BN 52021 on bacterial translocation in cerulein-induced pancreatitis. Eur Surg Res. 2004;36:136-141.
40. Hofbauer B, Saluja AK, Bhatia M, et al. Effect of recombinant platelet-activating factor acetylhydrolase on two models of experimental acute pancreatitis. Gastroenterology. 1998;115:1238-1247.
41. Whittaker M, Askew M, Beauchamp CL. Structure-activity relationships for BB-823 and related PAF-antagonists. J Lipid Mediators Cell Signal. 1994;10:151-152.
42. McKay CJ, Curran F, Sharples C, et al. Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis. Br J Surg. 1997;84:1239-1243.
43. Toh SKC, the British Acute Pancreatitis Study Group. Lexipafant, a platelet activating factor (PAF) antagonist reduces mortality in a randomized placebo controlled study in patients with severe acute pancreatitis. Gut. 1997;40(suppl):A12.
44. Johnson CD, Kingsnorth AN, Imrie CW, et al. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut. 2001;48:62-69.
45. Abu-Zidan FM, Windsor JA. Lexipafant and acute pancreatitis: a critical appraisal of the clinical trials. Eur J Surg. 2002;168:215-219.
46. Kaska M, Pospisilova B, Slizova D. Pathomorphological changes in microcirculation of pancreas during experimental acute pancreatitis. Hepatogastroenterology. 2000;47:1570-1574.
47. Hackert T, Pfeil D, Hartwig W, et al. Platelet function in acute experimental pancreatitis induced by ischaemia-reperfusion. Br J Surg. 2005;92:724-728.
48. Sakorafas GH, Tsiotou AG. Etiology and pathogenesis of acute pancreatitis: current concepts. J Clin Gastroenterol. 2000;30:343-356.
49. Gao HK, Zhou ZG, Chen YQ, et al. Expression of platelet endothelial cell adhesion molecule-1 between pancreatic microcirculation and peripheral circulation in rats with acute edematous pancreatitis. Hepatobiliary Pancreat Dis Int. 2003;2:463-466.
50. Gao HK, Zhou ZG, Han FH, et al. Differences in platelet endothelial cell adhesion molecule-1 expression between peripheral circulation and pancreatic microcirculation in cerulein-induced acute edematous pancreatitis. World J Gastroenterol. 2005;11:661-664.
51. Inoue K, Hirota M, Kimura Y, et al. Further evidence for endothelin as an important mediator of pancreatic and intestinal ischemia in severe acute pancreatitis. Pancreas. 2003;26:218-223.
52. Andrzejewska A, Dlugosz JW. The endothelin-1 receptor antagonists ameliorate histology and ultrastructural alterations in the pancreas and decrease trypsinogen activation in severe taurocholate pancreatitis in rats. Int J Exp Pathol. 2003;84:221-229.
53. Jagroop IA, Daskalopoulou SS, Mikhailidis DP. Endothelin-1 and human platelets. Curr Vasc Pharmacol. 2005;3:393-399.
54. Ma ZH, Ma QY. Resveratrol: a medical drug for acute pancreatitis. World J Gastroenterol. 2005;11:3171-3174.
55. Olas B, Wachowicz B, Saluk-Juszczak J, et al. Effect of resveratrol, a natural polyphenolic compound, on platelet activation induced by endotoxin or thrombin. Thromb Res. 2002;15:141-145.
56. Shigematsu S, Ishida S, Hara M, et al. Resveratrol, a red wine constituent polyphenol, prevents superoxide-dependent inflammatory responses induced by ischemia/reperfusion, platelet-activating factor, or oxidants. Free Radic Biol Med. 2003;34:810-817.
57. Wallerath T, Deckert G, Ternes T, et al. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation. 2002;106:1652-1658.
58. Foulis AK. Morphological study of the relation between accidental hypothermia and acute pancreatitis. J Clin Pathol. 1982;35:1244-1248.
59. Mikhailidis DP, Hutton RA, Dandona P. Effect of cooling on prostaglandin mediated inhibition of platelet aggregation. Clin Sci. 1981;61:28.
60. Mikhailidis DP, Hutton RA, Jeremy JY, et al. Hypothermia and pancreatitis. J Clin Pathol. 1983;36:483-484.
61. Jeremy JY, Mikhailidis DP, Dandona P. Simulating the diabetic environment modifies in vitro prostacyclin synthesis. Diabetes. 1983;32:217-221.
62. Mikhailidis DP, Ganotakis ES. Plasma albumin and platelet function: relevance to atherogenesis and thrombosis. Platelets. 1996;7:125-137.
63. Penner JA. Disseminated intravascular coagulation in patients with multiple organ failure of non-septic origin. Semin Thromb Hemost. 1998;24:45-52.
64. Carey MJ, Rodgers GM. Disseminated intravascular coagulation: clinical and laboratory aspects. Am J Hematol. 1998;59:65-73.
65. Satake K, Ha S, Hiura A, et al. Effect of a synthetic protease inhibitor (Fut-175) on coagulation abnormalities during experimental acute pancreatitis in dogs. Gastroenterol Jpn. 1990;25:720-726.
66. Moberg L, Johansson H, Lukinius A, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet. 2002;360:2039-2045.
67. Beuneu C, Vosters O, Movahedi B, et al. Human pancreatic duct cells exert tissue factor-dependent procoagulant activity. Diabetes. 2004;53:1407-1411.
68. Hirota M, Sugita H, Maeda K, et al. The concept of SIRS and severe acute pancreatitis. Nippon Rinsho. 2004;62:2128-2136.
69. Bogdanov VY, Balasubramanian V, Hathcock J, et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nature Med. 2003;9:458-462.
70. Versteeg HH. Tissue factor as an evolutionary conserved cytokine receptor: implications for inflammation and signal transduction. Semin Hematol. 2004;1(suppl 1):168-172.
71. Papadopoulos V, Tsangaris I, Giaglis S, et al. The pattern of F3 gene expression in human sepsis [abstract]. In: 9th State-of-the-Art Interdisciplinary Review Course on Pulmonary Diseases, Critical Care, Emergency Medicine and Nursing Care; April 22-24, 2005; Athens.
72. Price GC, Thompson SA, Kam PCA. Tissue factor and tissue factor pathway inhibitor. Anaesthesia. 2004;59:483-492.
73. Gando S, Kameue T, Matsuda N, et al. Imbalances between the levels of tissue factor and tissue factor pathway inhibitor in ARDS patients. Thromb Res. 2003;109:119-124.
74. Dobosz M, Mionskowska L, Hac S, et al. Heparin improves organ microcirculatory disturbances in caerulein-induced acute pancreatitis in rats. World J Gastroenterol. 2004;10:2553-2556.
75. Dobosz M, Wajda Z, Hac S, et al. Heparin and nitric oxide treatment in experimental acute pancreatitis in rats. Forum (Genova). 1998;8:303-310.
76. Goulbourne IA, Watson H, Davies GC. 111In-platelet and 125I-fibrinogen deposition in the lungs in experimental acute pancreatitis. J Surg Res. 1987;43:521-526.
77. Rabenstein T, Fischer B, Wiessner V, et al. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc. 2004;59:606-613.
78. Hackert T, Werner J, Gebhard MM, et al. Effects of heparin in experimental models of acute pancreatitis and post-ERCP pancreatitis. Surgery. 2004;135:131-138.
79. Murray B, Carter R, Imrie C, et al. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology. 2003;124:1786-1791.
80. Jaworek J, Bonior J, Tomaszewska R, et al. Involvement of cyclooxygenase-derived prostaglandin E2 and nitric oxide in the protection of rat pancreas afforded by low dose of lipopolysaccharide. J Physiol Pharmacol. 2001;52:107-126.
81. Harvey MH, Wedgwood KR, Reber HA. Vasoactive drugs, microvascular permeability, and hemorrhagic pancreatitis in cats. Gastroenterology. 1987;93:1296-1300.
82. Mentes A, Batur Y, Bayol U. Salycylate-induced pancreatic injury in the cat: a preliminary study. Rom J Gastroenterol. 2002;11:309-312.
83. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med. 2004;30:536-555.
84. Abraham E, Reinhart K, Opal S, et al, OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:256-258.
85. Pendurthi UR, Meng F, Mackman N, et al. Mechanism of resveratrol-mediated suppression of tissue factor gene expression. Thromb Haemost. 2002;87:155-162.